Posted inNephrology news
Pegcetacoplan Markedly Reduces Proteinuria in C3 Glomerulopathy and Immune‑Complex MPGN: Results from the VALIANT Phase 3 Trial
In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term safety profile.
